OpusPoint Partners

From Wikipedia, the free encyclopedia
OpusPoint Partners
TypePrivate Equity Investment Firm
IndustryPrivate equity
Founded2009
HeadquartersNew York, NY, United States
Key people
, Lindsay A. Rosenwald
ProductsVenture capital, Consulting
WebsiteOpusPoint

OpusPoint Partners, LLC is an investment advisory firm specializing in healthcare and life sciences.[1]

Background[]

Founded in 2009 by Michael S. Weiss and Lindsay A. Rosenwald, MD,[2] the firm acts as the investment manager for some portfolio private hedge funds in the healthcare and biotechnology sectors.[3]

In October 2010, OpusPoint invested approximately $3 million into National Holdings Corporation and formed a joint venture. As a result, a new investment banking firm, OPN Capital Markets, was established to leverage the resources of both companies.[4][5]

Among others, OpusPoint Partners participated in the private placement for such companies as Sunesis Pharmaceuticals, Inc. that developed Voreloxin, anticancer drug used in acute myeloid leukemia.[6]

References[]

  1. ^ "National Holdings Corporation Completes Equity Financing Led By OpusPoint Partners; Parties To Enter Into Strategic Alliance". reuters.com. 6 Oct 2010. Retrieved 2011-06-13.
  2. ^ "OpusPoint Partners History". opuspointpartners.com. Retrieved 2011-06-13.
  3. ^ "SECURITIES AND EXCHANGE COMMISSION (FORM 8-K)". markets.on.nytimes.com. 2011. Retrieved 2011-06-13.
  4. ^ "National Holdings Corporation Completes Equity Financing Led By OpusPoint Partners; Parties To Enter Into Strategic Alliance". reuters.com. 6 Oct 2010. Retrieved 2011-06-13.
  5. ^ "National Holdings Completes Equity Financing Led by OpusPoint Partners". DailyFinance.com. 6 Oct 2010. Retrieved 2011-06-13.
  6. ^ "Sunesis Closes $28.5 Million Final Tranche of 2009 Private Placement". finance.yahoo.com. June 30, 2010. Retrieved 2011-06-13.

External links[]


This article about investment is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""